Davidovitch Roy, Goch Abraham, Driesman Adam, Konda Sanjit, Pean Christian, Egol Kenneth
Department of Orthopaedic Surgery, NYU Hospital for Joint Diseases, New York, NY.
J Orthop Trauma. 2017 Aug;31(8):434-439. doi: 10.1097/BOT.0000000000000862.
To determine the efficacy of liposomal bupivacaine compared to placebo for postoperative pain control in patients undergoing operative fixation of ankle fractures.
Prospective single-blinded randomized control trial.
Academic Medical Center.
PATIENTS/PARTICIPANTS: After Institutional Review Board (IRB) approval, 76 patients who sustained an acute ankle fracture (OTA/AO 44A-C) requiring operative fixation met inclusion criteria.
Patients were randomly assigned to 1 of 2 groups, control (local intraoperative sterile saline injection under general anesthesia) or interventional (local intraoperative liposomal bupivacaine and bupivacaine injection under general anesthesia). Injections were administered in a standardized fashion and included injection of a 1:1 mixture of a 40 mL solution consisting of 1.3% Exparel and sterile saline (interventional) or a 40 mL injection of normal saline (control) into the surrounding periosteal, peritendinous, surrounding muscles and subcutaneous tissue of the surgical incision(s).
Pain medications administered and pain according to the Visual Analogue Scale was recorded at scheduled postoperative time points: 4, 24, 48, 72, and 336 hours (14 days).
Thirty-nine patients were randomized to the control group and 37 to the interventional group (mean age = 42 ± 15 years), with no statistically significant differences between groups with regards to severity of injury and patient demographics. Pain scores were significantly lower in the interventional group versus control up to 2 weeks after surgery. Percocet ingestion at 4 hours was significantly lower in the interventional group (0.7 vs. 1.3, P = 0.004), while it approached significance at 48 hours postoperatively (2.8 vs. 3.69, P = 0.07). No other significant differences were noted for Percocet ingestion postoperatively at other time points assessed. The overall satisfaction with pain control was not statistically different between the 2 groups (P = 0.93).
Local intraoperative infiltration of liposomal bupivacaine administered with standard bupivacaine for ankle fractures requiring Open Reduction Internal Fixation (ORIF) affords improved pain relief in the immediate postoperative period resulting in a reduction in Percocet ingestion, with resultant effects seen up to 2 days postoperatively. Continued investigation of this drug for use with extremity fractures is warranted.
Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
比较脂质体布比卡因与安慰剂对踝关节骨折手术固定患者术后疼痛控制的疗效。
前瞻性单盲随机对照试验。
学术医疗中心。
患者/参与者:经机构审查委员会(IRB)批准,76例急性踝关节骨折(OTA/AO 44A - C)需手术固定的患者符合纳入标准。
患者随机分为2组中的1组,对照组(全身麻醉下术中局部注射无菌生理盐水)或干预组(全身麻醉下术中局部注射脂质体布比卡因和布比卡因)。注射采用标准化方式,包括将由1.3%依帕列净和无菌生理盐水组成的40 mL溶液按1:1混合(干预组)或40 mL生理盐水(对照组)注射到手术切口周围的骨膜、肌腱周围、周围肌肉和皮下组织中。
在术后预定时间点:4、24、48、72和336小时(14天)记录使用的止痛药物和根据视觉模拟量表评估的疼痛情况。
39例患者随机分配至对照组,37例至干预组(平均年龄 = 42 ± 15岁),两组在损伤严重程度和患者人口统计学方面无统计学显著差异。术后2周内,干预组的疼痛评分显著低于对照组。干预组4小时时的羟考酮摄入量显著较低(0.7对1.3,P = 0.004),术后48小时时接近显著差异(2.8对3.69,P = 0.07)。在评估的其他时间点,术后羟考酮摄入量无其他显著差异。两组对疼痛控制的总体满意度无统计学差异(P = 0.93)。
对于需要切开复位内固定(ORIF)的踝关节骨折,术中局部浸润脂质体布比卡因与标准布比卡因可在术后即刻提供更好的疼痛缓解,导致羟考酮摄入量减少,术后2天仍有效果。有必要继续研究该药物在四肢骨折中的应用。
治疗水平I。有关证据水平的完整描述,请参阅作者指南。